Changes in US stocks | Both MRK.US (MRK.US) and Moderna (MRNA.US) stock prices have soared! Phase III trial of personalized mRNA cancer vaccine was successful

The Zhitong Finance App learned that on Wednesday, Merck (MRK.US) rose nearly 10% to $148.44. Moderna (MRNA.US) surged more than 113% to $134.51. According to the news, Moderna and MSD announced today that the personalized mRNA cancer vaccine jointly developed by the two companies achieved positive results in a large-scale phase III clinical trial, marking that mRNA technology ushered in the first successful phase III trial in the field of cancer treatment. It is also a major breakthrough in personalized immunotherapy in the history of cancer treatment.

According to a joint statement from the two companies, the InterPath-001 phase III trial reached the main end point and a key secondary endpoint — compared with the MSD immunization drug Keytruda alone, the vaccine combined with Keytruda can significantly reduce the risk of recurrence in melanoma patients after surgery and effectively inhibit the spread of tumors to distant organs. This is the first clinical protocol proven to be superior to Keytruda's monotherapy in adjuvant treatment of melanoma, and Keytruda has previously been the standard treatment option for this indication.